期刊文献+

二肽基肽酶-4心血管系统作用的研究进展 被引量:5

Review of cardiovascular effects of dipeptidyl peptidase 4
原文传递
导出
摘要 随着肠促胰素相关研究的不断深入,人们发现,二肽基肽酶-4(DPP-4)抑制剂除了降糖作用外,一些大型临床研究证实了其心血管系统的安全性,并可能通过降低心血管危险因素、改善血管内皮功能等机制起到心血管保护作用。然而,近期也有研究提出DPP-4抑制剂具有促进心力衰竭的可能。本文就DPP-4在心血管方面作用的研究进展进行文献综述。 Dipeptidyl peptidase-4 (DPP-4) inhibitors were long been proved their glucose lowering effects. As the studies on incretins were further developed, DPP-4 inhibitors were proved their cardiovascular safety in many clinic trails, and also showed possible cardiovascular protecting effect through controlling cardiac risk factors and regulating endothelial function. However, recent studies indicated that DPP-4 inhibitors might contribute to heart failure. This paper is a systemic literature review on the cardiovascular effects of DPP-4.
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2016年第11期1049-1051,共3页 Chinese Journal of Diabetes
关键词 二肽基肽酶-4 糖尿病 2型 心血管系统 Dipeptidyl peptidase 4 Diabetes mellitus, type 2 Cardiovascular system
  • 相关文献

参考文献1

二级参考文献10

  • 1Shani Ben-Shlomo,Isabel Zvibel,Mati Shnell,Amir Shlomai,Elena Chepurko,Zamir Halpern,Nir Barzilai,Ran Oren,Sigal Fishman.Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase[J].Journal of Hepatology.2010(6)
  • 2Alan Garber,Robert Henry,Robert Ratner,Pedro A Garcia-Hernandez,Hiromi Rodriguez-Pattzi,Israel Olvera-Alvarez,Paula M Hale,Milan Zdravkovic,Bruce Bode.Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial[J].The Lancet.2009(9662)
  • 3Hidekatsu Yanai,Hiroki Adachi,Hidetaka Hamasaki,Yoshinori Masui,Reo Yoshikawa,Sumie Moriyama,Shuichi Mishima,Akahito Sako.Effects of 6-Month Sitagliptin Treatment on Glucose and Lipid Metabolism, Blood Pressure, Body Weight and Renal Function in Type 2 Diabetic Patients: A Chart-Based Analysis[J].Journal of Clinical Medicine Research.2012(4)
  • 4Y.Furuta,M.Horiguchi,E.Sugaru,M.Ono‐Kishino,M.Otani,M.Sakai,Y.Masui,A.Tsuchida,Y.Sato,K.Takubo,H.Hochigai,H.Kimura,H.Nakahira,T.Nakagawa,M.Taiji.Chronic administration of DSP‐7238, a novel, potent, specific and substrate‐selective DPP IV inhibitor, improves glycaemic control and β‐cell damage in diabetic mice[J].Diabetes Obesity and Metabolism.2010(5)
  • 5J.Rosenstock,S.Sankoh,J. F.List.Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes*[J].Diabetes Obesity and Metabolism.2008(5)
  • 6Daniel J. Drucker.The biology of incretin hormones[J].Cell Metabolism.2006(3)
  • 7Daniel J Drucker,Michael A Nauck.The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J].The Lancet.2006(9548)
  • 8L.Blonde,E. J.Klein,J.Han,B.Zhang,S. M.Mac,T. H.Poon,K. L.Taylor,M. E.Trautmann,D. D.Kim,D. M.Kendall.Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes[J].Diabetes Obesity and Metabolism.2006(4)
  • 9Juris J. Meier.Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide[J].Best Practice & Research Clinical Endocrinology & Metabolism.2004(4)
  • 10Daniel J. Drucker.Biological actions and therapeutic potential of the glucagon-like peptides[J].Gastroenterology.2002(2)

共引文献3

同被引文献54

引证文献5

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部